Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000668298 | SCV000792873 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2017-07-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000668298 | SCV000834391 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2024-03-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asp772Asnfs*3) in the CAPN3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CAPN3 are known to be pathogenic (PMID: 10330340, 15689361). This variant is present in population databases (rs764086484, gnomAD 0.0009%). This premature translational stop signal has been observed in individuals with autosomal recessive limb-girdle muscular dystrophy (PMID: 7720071, 25135358). This variant is also known as 2313delAGAC. ClinVar contains an entry for this variant (Variation ID: 552945). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002499161 | SCV002809873 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A; Muscular dystrophy, limb-girdle, autosomal dominant 4 | 2024-06-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003459594 | SCV004213825 | pathogenic | Muscular dystrophy, limb-girdle, autosomal dominant 4 | 2023-11-30 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000668298 | SCV002085559 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2021-02-12 | no assertion criteria provided | clinical testing |